New drug aims to save lives from shock due to blood loss
NCT ID NCT05251181
First seen Jun 27, 2026 · Last updated Sep 18, 2026 · Updated 2 times
Summary
This study tests a new medicine called centhaquine for people in hypovolemic shock, a life-threatening condition where the body doesn't have enough blood flow. About 430 adults will receive either centhaquine or a placebo along with standard care. The main goal is to see if the drug lowers the chance of death within 28 days.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Phase 3
Large-scale testing in a bigger group. Usually the last step before a treatment can be approved.
- Participants
-
About 430 people
The number the study aims to enrol. It can still change while the study runs.
- Expected to start
-
Feb 2027
An estimate. Start dates often move.
- Expected to finish
-
Oct 2028
An estimate. End dates often move.
- Lead sponsor
-
A company
The lead sponsor is a pharmaceutical, biotech, or medical-device company.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
18 years and older
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: A subject will be eligible for inclusion in the study if he/she fulfils the following criteria: 1. Adult males or females aged 18 years or older. 2. Subjects with hypovolemic shock admitted to the hospital with systolic blood pressure ≤ 90 mm Hg at presentation, Mean Arterial Pressor (MAP) ≤ 65 mm Hg and continue to receive standard treatment of shock (endotracheal intubation; fluid resuscitation and vasopressors). Standard of care to be provided to the subject shall be the one used in that hospital. 3. Blood lactate level indicative of hypovolemic shock with lactate level more than 2 mmol/L. Exclusion Criteria: A subject will not be eligible for inclusion in this study if he/she meets any of the following exclusion criteria: 1. Subject with illness clinically defined as septic shock (Procalcitonin plasma levels of ≥0.5 ng/mL) or cardiogenic shock or neurogenic shock. 2. Subject for whom an etiology for hypovolemic shock cannot be determined on initial evaluation. 3. Hypovolemic shock due to traumatic brain injury, traumatic tamponade, traumatic tension pneumothorax, ventricular wall rupture. 4. Patient with altered consciousness not due to hypovolemic shock. 5. Subject with confirmed pregnancy. 6. Cardiopulmonary resuscitation (CPR) before randomization. 7. Presence of a do not resuscitate order. 8. Patient is participating in another interventional study. 9. Patients with systemic diseases which were already present before having trauma, such as: cancer, chronic renal failure, liver failure, decompensated heart failure or AIDS.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Hypovolemic shock are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
How to take part
Only the study team decides who joins. These are the ways to reach them.
-
The official record
ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.
-
A doctor treating you
A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.
More trials for these conditions
Other studies related to the condition(s) this trial covers.